全文获取类型
收费全文 | 26199篇 |
免费 | 1853篇 |
国内免费 | 139篇 |
专业分类
耳鼻咽喉 | 92篇 |
儿科学 | 1501篇 |
妇产科学 | 610篇 |
基础医学 | 2244篇 |
口腔科学 | 110篇 |
临床医学 | 2577篇 |
内科学 | 8065篇 |
皮肤病学 | 464篇 |
神经病学 | 2014篇 |
特种医学 | 241篇 |
外科学 | 2986篇 |
综合类 | 612篇 |
现状与发展 | 1篇 |
一般理论 | 6篇 |
预防医学 | 2253篇 |
眼科学 | 956篇 |
药学 | 1136篇 |
2篇 | |
中国医学 | 51篇 |
肿瘤学 | 2270篇 |
出版年
2024年 | 41篇 |
2023年 | 251篇 |
2022年 | 235篇 |
2021年 | 355篇 |
2020年 | 346篇 |
2019年 | 122篇 |
2018年 | 472篇 |
2017年 | 499篇 |
2016年 | 556篇 |
2015年 | 543篇 |
2014年 | 454篇 |
2013年 | 717篇 |
2012年 | 2021篇 |
2011年 | 2315篇 |
2010年 | 808篇 |
2009年 | 782篇 |
2008年 | 2503篇 |
2007年 | 2352篇 |
2006年 | 2029篇 |
2005年 | 2129篇 |
2004年 | 2085篇 |
2003年 | 2133篇 |
2002年 | 1704篇 |
2001年 | 1269篇 |
2000年 | 285篇 |
1999年 | 149篇 |
1998年 | 207篇 |
1997年 | 118篇 |
1996年 | 91篇 |
1995年 | 61篇 |
1994年 | 75篇 |
1993年 | 36篇 |
1992年 | 44篇 |
1991年 | 32篇 |
1990年 | 42篇 |
1989年 | 40篇 |
1988年 | 38篇 |
1987年 | 42篇 |
1986年 | 39篇 |
1985年 | 26篇 |
1984年 | 25篇 |
1983年 | 13篇 |
1982年 | 17篇 |
1981年 | 19篇 |
1980年 | 13篇 |
1979年 | 7篇 |
1978年 | 12篇 |
1977年 | 6篇 |
1974年 | 4篇 |
1970年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
中医疗效系统评价体系的研究 总被引:12,自引:0,他引:12
中医现代化科技发展战略研究课题组 《世界科学技术》2002,4(2):12-14
临床疗效是中医药学生存在和发展的基础。建立中医临床疗效系统评价体系。对于科学、客观、系统地开展中医临床疗效的评价具有重要意义。本文研究并探讨了建立中医临床疗效系统评价体系所需达到的目标和发展思路,提出了建立该系统的重点任务及关键技术。 相似文献
92.
93.
Working Group on Pediatric Acute Rheumatic Fever Cardiology Chapter of Indian Academy of Pediatrics Saxena A Kumar RK Gera RP Radhakrishnan S Mishra S Ahmed Z 《Indian pediatrics》2008,45(7):565-573
JUSTIFICATION: Acute rheumatic fever and rheumatic chronic valvular heart disease is an important preventable cause of morbidity and mortality in suburban and rural India. Its diagnosis is based on clinical criteria. These criteria need verification and revision in the Indian context. Furthermore, there are glaring differences in management protocols available in literature. These facts prompted Indian Academy of Pediatrics to review the management of rheumatic fever. PROCESS: Management of Rheumatic fever was reviewed and recommendation was formulated at national consultative meeting on 20th May 2007 at New Delhi. OBJECTIVES: To formulate uniform guidelines on management of acute rheumatic fever and rheumatic heart disease in the Indian context. Guidelines were formulated for the management of streptococcal pharyngitis, acute rheumatic fever and its cardiac complication as well as secondary prophylaxis for recurrent episodes. RECOMMENDATIONS: (1) Streptococcal eradication with appropriate antibiotics (Benzathine penicillin single dose or penicillin V oral or azithromycin). (2) Diagnosis of rheumatic fever based on Jones criteria. (3) Control inflammatory process with aspirin with or without steroids (total duration of treatment of 12 weeks). (4) Treatment of chorea according to severity (therapy to continue for 2-3 weeks after clinical improvement). (5) Protocol for managing cardiac complication like valvular heart disease, congestive heart failure and atrial fibrillation. (6) Secondary prophylaxis with benzathine penicillin and management of anaphylaxis. 相似文献
94.
95.
96.
97.
目的:为了提高噻二唑的收率。方法:以水合肼为原料经酰化、成盐、环合、精制四步合成了药物中间体噻二唑。结果:总收率达68%。结论:本方法具有操作安全、工艺简单、收率高等特点。 相似文献
98.
Takeyama K Ogura M Morishima Y Kasai M Kiyama Y Ohnishi K Mitsuya H Kawano F Masaki Y Sasaki T Chou T Yokozawa T Tobinai K;Lenograstim/Lymphoma Study Group 《Japanese journal of clinical oncology》2003,33(2):78-85
BACKGROUND: Peripheral blood stem cell (PBSC) reinfusion has been widely used for hematopoietic reconstitution after high-dose chemotherapy. However, the optimal dose of granulocyte colony-stimulating factor (G-CSF) for PBSC mobilization in combination with chemotherapy for autograft remains unknown. METHODS: To find the optimal dose of glycosylated G-CSF (lenograstim) for PBSC mobilization in combination with chemotherapy for aggressive non-Hodgkin's lymphoma (NHL), we conducted a dose-finding study on 43 newly diagnosed patients who had unfavorable prognostic factors. They received four to six courses of cyclophosphamide, doxorubicin, vincristine and prednisolone combined with lenograstim every 2 weeks (biweekly CHOP therapy). PBSC apheresis was started after the third course of biweekly CHOP therapy. Lenograstim was given daily from day 3 until the day of the last apheresis. The optimum dose of lenograstim was assessed based on mobilization efficacy and safety profiles at a daily single dose of 2, 5 and 10 microg/kg for eight patients in each level. RESULTS: The collected number of CD34+ cells in the first apheresis products was higher in the 5 microg/kg group than in the 2 microg/kg group (median, 4.22 x 10(6) vs 2.49 x 10(6) CD34+ cells/kg, P = 0.051). The highest dose of 10 microg/kg (median, 2.99 x 10(6) CD34+ cells/kg) failed to show a dose dependence in PBSC mobilization. The efficacy and safety of the 5 microg/kg dose were further confirmed in an additional 19 patients. CONCLUSIONS: The present study suggests that the recommended dose of lenograstim for PBSC mobilization with CHOP therapy in untreated NHL is 5 microg/kg. 相似文献
99.
100.
Darcy KM Brady WE McBroom JW Bell JG Young RC McGuire WP Linnoila RI Hendricks D Bonome T Farley JH;Gynecologic Oncology Group 《Gynecologic oncology》2008,111(3):487-495
ObjectiveThe Gynecologic Oncology Group (GOG) performed a detailed analysis of p53 overexpression in previously-untreated women with invasive early or advanced stage epithelial ovarian cancer (EOC).MethodsWomen were eligible for the study if they provided a tumor block for translational research and participated in either GOG-157, a randomized phase III trial of three versus (vs.) six cycles of paclitaxel + carboplatin in high-risk, early stage EOC, or GOG-111, a randomized phase III trial of cyclophosphamide + cisplatin vs. paclitaxel + cisplatin in suboptimally-resected, advanced stage EOC. The N-terminal DO-7 p53 antibody was used to examine the expression of the major normal and mutant p53-isoforms. p53 overexpression was defined as ≥ 10% tumor cells exhibiting nuclear staining.Resultsp53 was overexpressed in 51% (73/143) and 66% (90/136) of cases in the GOG-157 and GOG-111 cohorts, respectively. In the GOG-157 cohort, p53 overexpression was not associated with any clinical characteristics or overall survival (OS) but was associated with worse progression-free survival (PFS) (logrank test: p = 0.013; unadjusted Cox modeling: p = 0.015). In the GOG-111 cohort, p53 overexpression was associated with GOG performance status (p = 0.018) and grade (p = 0.003), but not with age, stage, cell type or with tumor response and disease status after primary chemotherapy, PFS or OS. Adjusted Cox regression modeling demonstrated that p53 overexpression was not an independent prognostic factor for PFS or OS in either cohort.Conclusionsp53 overexpression assessed by DO-7 immunostaining is common in early and advanced stage EOC, but has limited prognostic value in women treated with surgical staging and platinum-based combination chemotherapy. 相似文献